A Research Guide for
Desmoid Tumors (Aggressive Fibromatosis)

These arise outside the abdominal cavity — in the extremities (arms, legs), trunk, chest wall, head, or neck. They are the most common type in the general population. Extra-abdominal desmoids can cause pain, restrict movement, and compress nearby nerves or blood vessels. Those in the extremities may affect limb function, especially when they grow near joints or wrap around nerves. Head and neck desmoids are particularly challenging because of the density of vital structures in these areas.

Extra-abdominal desmoids generally have a somewhat better prognosis than intra-abdominal desmoids, partly because they are easier to monitor with imaging and partly because they are less likely to threaten vital organs. However, they can still cause significant morbidity, particularly through pain and functional impairment.

These grow within the muscles and fascia of the abdominal wall. They are particularly common in women of childbearing age and may develop during or after pregnancy, or at the site of a previous surgical incision (such as a cesarean section). Abdominal wall desmoids are generally the most favorable type — they tend to have lower recurrence rates after surgery (when surgery is performed), they are relatively accessible for monitoring and treatment, and they rarely threaten vital internal structures. Many are excellent candidates for active surveillance.

These grow within the mesentery — the fan-shaped tissue that suspends and supplies blood to the intestines. Intra-abdominal desmoids are particularly associated with familial adenomatous polyposis (FAP), where they often develop after colectomy surgery. They are the most challenging type because of their proximity to the intestines and major blood vessels. They can cause bowel obstruction, compress or encircle vital blood vessels (particularly the superior mesenteric artery and vein), and lead to bowel ischemia in severe cases.

Surgery for intra-abdominal desmoids carries significant risk because the tumor is often intertwined with critical structures. This is one of the strongest reasons the field has moved toward non-surgical management as the first approach. Mesenteric desmoids in FAP patients are a leading cause of morbidity and death in that population.

In rare cases, desmoid tumors arise at multiple sites simultaneously or sequentially. This is more common in FAP patients and can also occur sporadically. Multifocal disease further reinforces the rationale for systemic (drug-based) therapy rather than surgery, since local treatments cannot address tumors at multiple sites.

The majority of desmoid tumors (roughly 85–90%) occur sporadically — meaning they are not associated with any inherited condition. In these cases, the tumor arises from a spontaneous mutation in the CTNNB1 gene in a single cell. Several factors have been associated with increased risk:

• Trauma or surgery: Desmoid tumors sometimes develop at sites of previous surgical incisions, wounds, or trauma. This association is well documented but poorly understood mechanistically.
• Pregnancy and hormonal factors: The association with pregnancy and estrogen exposure has been noted for decades. Abdominal wall desmoids are more common in women of reproductive age, and some tumors have been observed to grow during pregnancy and regress after menopause. However, the relationship between hormones and desmoid tumors is complex and not fully established — many patients are male, postmenopausal, or have no clear hormonal link.
• Age: Peak incidence is between 25 and 35 years of age, but desmoid tumors can occur at any age, including in children and the elderly.

As with any disease, having risk factors does not mean someone caused their tumor, and many patients have no identifiable risk factor at all.

Familial adenomatous polyposis (FAP) is an inherited condition caused by mutations in the APC gene. Patients with FAP develop hundreds to thousands of polyps in the colon and require colectomy, usually in early adulthood. Desmoid tumors develop in approximately 10–30% of FAP patients, and they are a major source of morbidity and mortality in this population — second only to colorectal cancer itself.

In FAP patients, desmoid tumors most commonly arise in the mesentery (intra-abdominal), often within 1–5 years after abdominal surgery. Certain APC mutation locations (particularly mutations downstream of codon 1399, near the 3’ end of the gene) are associated with higher desmoid risk, though desmoids can occur with any FAP-causing mutation.

Any patient diagnosed with a desmoid tumor, particularly an intra-abdominal one, should be evaluated for FAP with a thorough family history, consideration of colonoscopy, and potentially APC genetic testing. If FAP is confirmed, the management must be coordinated to address both the polyposis and the desmoid disease.

Gardner syndrome is a variant of FAP characterized by the combination of colonic polyposis with extra-intestinal features including desmoid tumors, osteomas (benign bone growths, often in the jaw), epidermoid cysts, and other soft tissue tumors. It is caused by the same APC gene mutations. The term is used less frequently in modern practice, as the features are recognized as part of the FAP spectrum, but patients may encounter it in older literature or when explaining their condition.

• Spontaneous regression: A meaningful proportion of desmoid tumors shrink or even disappear entirely without any treatment. Published series report spontaneous regression rates of 10–28%.
• Stabilization: Many desmoid tumors grow to a certain size and then stop. When combined with those that regress, roughly 50% or more of untreated desmoid tumors will stabilize or improve over time.
• Slow growth: Some tumors grow slowly and steadily, eventually requiring treatment because of symptoms or functional impairment.
• Rapid growth: A minority of desmoid tumors grow rapidly and require prompt treatment. This is more common in younger patients, intra-abdominal tumors, and certain CTNNB1 mutation types.
• Cyclic behavior: Some tumors grow, stabilize, and even partially regress in cycles, making it difficult to judge treatment effect versus natural variation.

This unpredictable behavior is the scientific basis for the current recommendation of active surveillance as the first approach. Because so many tumors will stabilize or improve on their own, starting treatment immediately would mean treating many patients who never needed it — and exposing them to side effects or surgical complications unnecessarily.

Desmoid tumors almost never cause death. The main exception is intra-abdominal desmoid tumors (particularly mesenteric desmoids in FAP patients) that can obstruct or compromise blood supply to the intestines. Overall mortality from desmoid tumors is very low, estimated at less than 5% even in historical series before modern management.

However, desmoid tumors can cause significant morbidity — chronic pain, functional limitation, and impact on quality of life. They are often a chronic condition rather than a curable one, and the goal of management is frequently long-term control and symptom management rather than complete eradication. Patients should be prepared for a potentially long-term relationship with their medical team.

• Anecdotes instead of trials: Any treatment claim based only on individual stories rather than controlled studies should be viewed skeptically. A tumor that shrank after a supplement may simply have undergone spontaneous regression.
• Claims of “curing” desmoid tumors: No current treatment cures desmoid tumors reliably. Even nirogacestat, the most effective drug, is a management tool, not a cure. Be wary of anyone promising a cure.
• Pressure to act immediately: Desmoid tumors rarely require emergency treatment. With very few exceptions (bowel obstruction, vascular compromise), there is time to get a second opinion and make careful decisions.
• Practitioners unfamiliar with the disease: If a doctor recommends immediate surgery as the obvious first step, they may not be current with desmoid tumor management. Seek a sarcoma specialist for a second opinion.

Make sure you understand clearly that this is not cancer. This single fact changes the entire framework for thinking about your condition. Desmoid tumors do not spread to other organs. They are locally aggressive growths of connective tissue. The outlook is fundamentally different from a cancer diagnosis.

Ask your doctor whether they have experience treating desmoid tumors. If the answer is no or very limited, ask for a referral to a sarcoma center. This is not an insult to your doctor — desmoid tumors are rare enough that most physicians, including most oncologists, have limited experience with them. Expert management genuinely makes a difference.

• Where exactly is my tumor, and what is its current size?
• Is this a sporadic tumor, or could it be associated with FAP? Should I be tested?
• Has CTNNB1 mutation testing been done or ordered?
• Is the tumor currently causing symptoms, or was it found incidentally?
• Is active surveillance appropriate for my situation, and what would the monitoring schedule look like?
• Should I be referred to a sarcoma center for a second opinion?
• What imaging will be used to monitor the tumor, and how often?

The definitive diagnosis requires a biopsy — a tissue sample examined under the microscope by a pathologist. Core needle biopsy is usually preferred over excisional (surgical) biopsy, because it provides adequate tissue for diagnosis without the need for surgery. In the era of active surveillance, performing surgery to diagnose a tumor that may then be observed defeats the purpose.

Key pathology findings in desmoid tumors include:

• Bland fibroblasts: The cells look relatively normal (not the wild, disordered cells seen in sarcomas) but are growing in dense, infiltrative bundles.
• Nuclear beta-catenin staining: Immunohistochemistry showing beta-catenin accumulation in the cell nuclei is a hallmark of desmoid tumors and helps confirm the diagnosis.
• CTNNB1 mutation testing: Molecular testing for CTNNB1 mutations provides additional diagnostic confirmation and may have prognostic value.
• No significant mitotic activity or necrosis: These features, which would suggest a sarcoma, are absent or minimal in desmoid tumors.

Pathology review at a center experienced with soft tissue tumors is strongly recommended. Misdiagnosis — particularly confusion with low-grade fibromyxoid sarcoma or other fibroblastic tumors — can lead to inappropriate treatment.

MRI (magnetic resonance imaging) is the preferred imaging modality for desmoid tumors in most locations. It provides excellent soft tissue contrast, shows the tumor’s relationship to surrounding structures, and is critical for monitoring on active surveillance. Key MRI features of desmoid tumors include:

• Low to intermediate signal on T1-weighted images
• Variable signal on T2-weighted images (high signal may correlate with active/cellular tumor; low signal may indicate mature, fibrous tissue)
• Enhancement with gadolinium contrast
• Infiltrative margins blending into surrounding tissue

T2 signal changes on MRI may be useful for monitoring: a shift from high T2 signal to low T2 signal over time can suggest the tumor is maturing and stabilizing, even if the overall size has not changed dramatically.

CT (computed tomography) is the primary imaging modality for intra-abdominal (mesenteric) desmoid tumors, where bowel motion artifacts can make MRI less useful. CT also provides better assessment of the relationship between the tumor and mesenteric blood vessels.

PET scans are not routinely used for desmoid tumors and are generally not helpful, as desmoid tumors have variable and unpredictable metabolic activity.

Every patient with a newly diagnosed desmoid tumor should be assessed for possible FAP, especially if the tumor is intra-abdominal, the patient is young, or there is any family history of colon polyps, colon cancer, or other FAP-related features (osteomas, epidermoid cysts). The evaluation typically includes:

• Detailed family history: Focusing on colon cancer, polyps, and FAP-associated features across three generations.
• Genetic counseling and testing: APC gene sequencing if FAP is suspected.
• Colonoscopy: To look for polyposis if not previously performed.

Identifying FAP changes the entire management plan because the patient will need lifelong surveillance and management for both the polyposis and the desmoid disease.

Active surveillance is not “doing nothing.” It is a structured, deliberate management strategy that includes:

• Regular imaging: MRI (or CT for intra-abdominal tumors) every 3–6 months initially, with intervals potentially lengthening to every 6–12 months if the tumor remains stable. The NCCN recommends monitoring at 1–2 month intervals initially for the first year, then extending intervals if stable.
• Symptom assessment: Regular evaluation of pain, function, and quality of life at each visit.
• Pain management: Proactive treatment of any pain or discomfort, independent of whether the tumor itself is being treated.
• Clear trigger criteria: A pre-defined agreement between you and your doctor about what would prompt a shift from surveillance to active treatment (rapid growth, worsening symptoms, threat to vital structures).

Multiple retrospective and prospective studies have validated active surveillance:

• The French Sarcoma Group published a landmark prospective study showing that among patients managed with initial observation, the 2-year progression-free rate without treatment was approximately 50–60%. Many patients who initially progressed later stabilized.
• The placebo arm of the Alliance A091105 sorafenib trial (NCT02066181) provided prospective data on the natural history of untreated desmoid tumors, supporting the feasibility and safety of initial observation in many patients.
• A large retrospective study from Memorial Sloan Kettering of 142 patients managed with active surveillance found that only about 25% eventually required intervention.

Both NCCN and ESMO-EURACAN guidelines now recommend active surveillance as the initial approach for desmoid tumors that are not causing significant symptoms or threatening vital structures.

There are situations where immediate treatment rather than observation is indicated:

• Tumor is causing or threatening bowel obstruction (intra-abdominal desmoids)
• Tumor is compressing or encircling major blood vessels
• Tumor is compressing vital nerves with progressive neurological deficit
• Severe, intractable pain not responsive to pain management
• Rapid tumor growth documented on serial imaging
• Significant functional impairment (such as loss of limb function)

Even in these situations, systemic medical therapy (particularly nirogacestat) is now often preferred over surgery as the first intervention.

The general order of preference for desmoid tumors requiring treatment, based on current guidelines and expert consensus:

1. Nirogacestat (Ogsiveo): The only FDA-approved therapy specifically for desmoid tumors. Now considered the preferred first systemic therapy when treatment is needed.
2. Other systemic therapies: Sorafenib, low-dose chemotherapy (methotrexate with vinblastine or vinorelbine), anti-estrogen therapy (tamoxifen), and NSAIDs — these have been used for years and remain options, particularly when nirogacestat is not available or not tolerated.
3. Surgery: Reserved primarily for situations where the tumor is clearly resectable with acceptable morbidity, has failed medical therapy, or is in a location where surgery is straightforward (such as some abdominal wall tumors).
4. Other local therapies: Radiation, cryoablation, radiofrequency ablation, and high-intensity focused ultrasound (HIFU) are used selectively in specific situations.

The specific approach is individualized based on tumor location, size, growth rate, symptoms, the patient’s overall health, and the local expertise available.

The DeFi trial was a randomized, double-blind, placebo-controlled phase III trial that enrolled 142 patients with progressing desmoid tumors. Patients were assigned to receive either nirogacestat (150 mg twice daily) or placebo. The key results:

• Objective response rate: 41% of patients treated with nirogacestat had their tumors shrink by 30% or more (partial or complete response), compared to 8% with placebo.
• Progression-free survival: Nirogacestat dramatically reduced the risk of tumor progression compared to placebo, with a hazard ratio of 0.29 (meaning roughly 71% reduction in risk of progression).
• Symptom improvement: Patients on nirogacestat reported significant improvements in pain, physical function, and quality of life compared to placebo.
• Complete responses: Some patients achieved complete disappearance of their tumors on imaging.

The DeFi trial was particularly important because it was one of the few randomized controlled trials ever conducted specifically for desmoid tumors, and the results were unambiguous.

Nirogacestat inhibits gamma-secretase, an enzyme complex involved in the Notch signaling pathway. In desmoid tumors, Notch signaling cross-talks with the aberrant Wnt/beta-catenin pathway that drives tumor growth. By blocking gamma-secretase, nirogacestat disrupts this signaling and inhibits the proliferation of the tumor fibroblasts.

The drug is taken orally, typically 150 mg twice daily. Tumor response is usually gradual — it may take several months before imaging shows significant shrinkage. Patients should not expect immediate results and should discuss realistic timelines with their doctor.

Nirogacestat has a distinct side-effect profile that patients should be aware of:

• Diarrhea: The most common side effect, occurring in a majority of patients. Usually manageable with anti-diarrheal medications and dose adjustment.
• Ovarian toxicity: Nirogacestat can cause ovarian dysfunction, including ovarian failure, in premenopausal women. This is a serious consideration for women of reproductive age. Fertility preservation should be discussed before starting treatment.
• Skin reactions: Rash, maculopapular eruptions, and other skin toxicities are common.
• Fatigue: Reported by many patients.
• Nausea and vomiting: Usually mild to moderate.
• Phosphate abnormalities: Hypophosphatemia (low blood phosphate) requires monitoring.
• Hair changes: Alopecia and hair color changes have been reported.

The ovarian toxicity is the most important counseling point for premenopausal women. If future fertility is desired, options such as egg or embryo freezing should be explored with a reproductive endocrinologist before starting nirogacestat.

• Duration of therapy: The optimal duration is not yet established. Some patients remain on nirogacestat long-term; others may be able to stop after achieving a response, though the risk of regrowth after discontinuation is not yet well characterized.
• Cost and access: Nirogacestat is expensive. SpringWorks Therapeutics (the manufacturer) offers a patient assistance program (SpringWorksAssist). Patients should work with their treatment center’s financial counseling office and the manufacturer’s access program.
• Monitoring: Regular blood work (including phosphate levels), imaging, and assessment of side effects are needed during treatment.
• Drug interactions: Nirogacestat is metabolized by CYP3A4 enzymes. Strong CYP3A4 inhibitors and inducers should be avoided or used with caution. Inform your medical team of all medications, supplements, and herbal products you are taking.

Sorafenib is an oral multikinase inhibitor originally developed for kidney and liver cancer. The Alliance A091105 trial (NCT02066181) was a randomized, placebo-controlled phase III trial that demonstrated sorafenib’s activity in desmoid tumors. Key results showed an objective response rate of approximately 33% with sorafenib versus 20% with placebo, and significantly improved progression-free survival.

Common side effects include hand-foot skin reaction, diarrhea, fatigue, rash, and hypertension. The typical dose is 400 mg daily (lower than the standard cancer dose of 800 mg daily), which helps manage toxicity.

Sorafenib is used off-label for desmoid tumors (it does not have an FDA-approved indication for this condition). It remains a reasonable option, particularly in settings where nirogacestat is not available.

The combination of low-dose methotrexate with a vinca alkaloid (vinblastine or, more recently, vinorelbine as a better-tolerated substitute) has been used for decades to treat desmoid tumors, particularly in pediatric patients and young adults. This is a low-intensity regimen given weekly, very different from the aggressive chemotherapy used in cancer treatment.

Response rates are modest (partial responses in roughly 30–40% of patients), but the regimen is generally well tolerated, and many patients achieve disease stabilization. Treatment is typically given for 6–12 months. The main side effects are mild nausea, low blood counts (requiring monitoring), and liver enzyme elevations from methotrexate.

Vinorelbine (oral or IV) has largely replaced vinblastine in modern practice because it is better tolerated and easier to administer.

Tamoxifen and other anti-estrogen drugs have been used for desmoid tumors for several decades, based on the observation that some desmoid tumors express estrogen receptors and that hormonal factors seem to play a role in their development. The evidence for their efficacy is limited to case series and retrospective studies rather than randomized trials.

Response rates are modest, with partial responses reported in roughly 15–25% of patients and stabilization in many others. Tamoxifen is generally well tolerated but carries risks including blood clots (deep vein thrombosis and pulmonary embolism), hot flashes, and a small increased risk of endometrial cancer with long-term use.

Given the availability of more effective therapies (nirogacestat, sorafenib), anti-estrogen therapy is now less commonly used as a primary systemic treatment, but it may still have a role in mild or slowly progressive disease, or in combination with NSAIDs.

Non-steroidal anti-inflammatory drugs, particularly sulindac and celecoxib (Celebrex), have been used for desmoid tumors based on the theory that cyclooxygenase (COX) pathway inhibition may reduce fibroblast proliferation. Sulindac is particularly used in FAP-associated desmoids, where it has dual utility (it also helps control colonic polyp burden).

The evidence base consists of case series and small studies. Response rates as single agents are low, and NSAIDs are more commonly used in combination with tamoxifen (the “sulindac plus tamoxifen” regimen) or as part of a conservative initial approach for mild disease. Long-term NSAID use carries gastrointestinal and cardiovascular risks that must be weighed.

For rapidly progressive or refractory desmoid tumors that have not responded to other therapies, pegylated liposomal doxorubicin (Doxil) has been used. This is a more aggressive chemotherapy approach with higher response rates (reported at 40–60% in some series) but also more significant side effects, including hand-foot syndrome, mucositis, and potential cardiac toxicity with cumulative dosing. It is generally reserved for cases where other options have failed or where rapid tumor control is needed.

Two facts drove the change away from surgery as the primary treatment:

• High recurrence rates: Desmoid tumors recur after surgery in roughly 25–70% of cases, depending on the series. The infiltrative growth pattern makes it difficult to achieve truly clear margins, and even when margins appear clear, recurrence is common. Recurrent tumors are often larger, harder to manage, and may require more aggressive treatment.
• Many tumors do not need treatment at all: With the recognition that roughly half of desmoid tumors stabilize or regress spontaneously, performing surgery on all tumors means subjecting many patients to unnecessary procedures with significant complication risks and high recurrence rates.

The NCCN guidelines now state that surgery should be considered carefully and that observation and medical therapy should be exhausted first in many situations. The ESMO-EURACAN guidelines are even more explicit in de-emphasizing surgery.

• Small, well-localized abdominal wall tumors that can be removed with clear margins and acceptable cosmetic or functional outcome.
• Tumors that have failed medical therapy and continue to grow or cause symptoms.
• Tumors in locations where surgery is technically straightforward and the risk of recurrence is lower.
• Emergency situations such as bowel obstruction or vascular compromise (though even here, initial medical stabilization is preferred when possible).

If surgery is being considered, it should be performed by a surgeon experienced with desmoid tumors at a sarcoma center. The goal is R0 resection (microscopically clear margins), but positive margins do not automatically mean recurrence, and re-excision for positive margins alone is not always recommended.

There has been longstanding debate about whether achieving clear (negative, R0) surgical margins reduces recurrence in desmoid tumors. Some studies have shown a correlation between negative margins and lower recurrence, while others have not. The infiltrative nature of desmoid tumors means that even wide excisions can leave behind microscopic disease that is not detected at the margin.

Current consensus: clear margins are desirable, but the decision to perform more extensive surgery solely to achieve clear margins must be weighed against the functional and cosmetic costs. A positive margin in a patient whose tumor was otherwise well controlled may be managed with observation rather than immediate re-excision.

Radiation therapy has been used for desmoid tumors in two settings: as definitive treatment (without surgery) and as adjuvant treatment after surgery (to reduce recurrence risk). Local control rates of 70–80% have been reported with radiation alone. However, radiation carries long-term risks including fibrosis, secondary malignancies (particularly concerning in young patients who make up most of the desmoid population), and functional impairment. Its use has declined with the availability of effective systemic therapies.

Current guidelines generally reserve radiation for situations where other local and systemic therapies have been exhausted and the tumor is causing significant local problems in a location amenable to radiation.

Percutaneous cryoablation (freezing the tumor through a needle inserted under imaging guidance) has shown promising results for extra-abdominal desmoid tumors. Studies have reported high local control rates (70–90%) with relatively low morbidity compared to surgery. It is particularly useful for tumors in locations where surgery would be challenging or morbid.

Radiofrequency ablation (RFA) uses heat instead of cold and has also been reported in small series. Both techniques are best performed at centers with experience in musculoskeletal interventional procedures.

These ablative techniques are increasingly used as alternatives to surgery, though long-term data are still accumulating. They work best for tumors under 5–10 cm that are accessible to percutaneous approach.

HIFU is a non-invasive technique that uses focused ultrasound waves to destroy tissue with heat. It has been explored for desmoid tumors but remains investigational. Early results are mixed, and its role relative to cryoablation and systemic therapy is not yet established. It is available at very few centers.

• Usually intra-abdominal: Most FAP-associated desmoids arise in the mesentery after colectomy.
• Often triggered by surgery: Abdominal surgery for polyposis or other indications can precipitate desmoid development. This creates a difficult paradox: patients need colectomy to prevent colon cancer, but the surgery itself can trigger desmoid disease.
• Can be life-threatening: Mesenteric desmoids in FAP patients can obstruct the intestines, compromise blood supply to the bowel, and cause severe complications. They are the second leading cause of death in FAP after colorectal cancer.
• May be multifocal: Multiple desmoid tumors can arise simultaneously in the mesentery.
• Classified by the Church staging system: Stage I (asymptomatic, <10 cm, not growing), Stage II (mildly symptomatic, 10–20 cm, slowly growing), Stage III (symptomatic, >20 cm or growing rapidly), Stage IV (causing bowel or ureteral obstruction or perforation).

• Avoid surgery when possible. This is even more important for FAP mesenteric desmoids than for sporadic desmoids, because the surgical field is often hostile (adhesions, altered anatomy from prior colectomy) and the recurrence rate after surgery is very high.
• Sulindac: NSAIDs, particularly sulindac, have been a mainstay for FAP desmoids because they address both polyp and desmoid disease. They are often used as first-line medical therapy, sometimes in combination with tamoxifen.
• Nirogacestat and sorafenib: These systemic agents are applicable to FAP desmoids just as they are to sporadic desmoids. The DeFi trial included FAP patients.
• Coordinate care: FAP patients need integrated care from a gastroenterologist (for polyp surveillance), genetic counselor, surgical oncologist, and the sarcoma team managing the desmoid. Few centers manage all these aspects well.
• Pre-surgical desmoid risk assessment: Before performing colectomy in a FAP patient known to carry high-risk APC mutations (especially mutations beyond codon 1399), the surgical team should discuss desmoid risk and consider strategies to minimize it, such as avoiding unnecessary re-operations.

• DeFi (NCT03785964): The pivotal phase III trial of nirogacestat that led to FDA approval. Completed. Results published in the New England Journal of Medicine in 2023.
• Alliance A091105 (NCT02066181): A randomized, placebo-controlled phase III trial of sorafenib for desmoid tumors. Demonstrated sorafenib’s activity and validated the role of systemic therapy.
• DESMOPAZ (NCT01876082): A randomized phase II trial comparing pazopanib (another tyrosine kinase inhibitor) with methotrexate-vinblastine in desmoid tumors. Published results supported the activity of pazopanib.
• NCT03459469: A phase II trial of tegavivint (BC2059), a beta-catenin/TBL1 inhibitor, in desmoid tumors. This drug directly targets the beta-catenin pathway. (Verify enrollment status on ClinicalTrials.gov.)
• NCT02476305: A study evaluating cryoablation for desmoid tumors, building the evidence base for this minimally invasive approach.
• NCT04871282 (RINGSIDE): A phase 2/3 trial of AL102, another gamma-secretase inhibitor, being evaluated in progressing desmoid tumors.

• Start with the treating center’s clinical trials office. Sarcoma centers that treat desmoid tumors usually have the most relevant trials.
• Search ClinicalTrials.gov — use the search term “desmoid” or “aggressive fibromatosis” and filter by “Recruiting” status.
• Desmoid Tumor Research Foundation (DTRF): Maintains a list of active trials and can help connect patients. dtrf.org
• Sarcoma Alliance for Research through Collaboration (SARC): A research consortium that runs sarcoma trials, including desmoid tumor trials. sarctrials.org
• National Cancer Institute (NCI): 1-800-4-CANCER. Can help identify trials nationally.

Trial enrollment moves faster when paperwork is assembled in advance. Keep ready: all pathology reports (with CTNNB1 mutation status), imaging reports and images (MRI and/or CT), operative reports from any prior surgeries, a complete medication list, full medical history, recent lab results, and insurance information. By federal law, most insurance plans must cover the routine care costs of clinical trial participation, and the experimental drug is generally provided at no cost by the trial sponsor.

The success of nirogacestat has validated gamma-secretase inhibition as a mechanism for treating desmoid tumors. Several other gamma-secretase inhibitors are in development:

• AL102: Another gamma-secretase inhibitor being evaluated in the phase 2/3 RINGSIDE trial (NCT04871282). If effective and tolerated differently from nirogacestat, it could provide an alternative for patients who do not respond to or cannot tolerate nirogacestat.

Since desmoid tumors are driven by aberrant beta-catenin accumulation, drugs that directly target this pathway are of great interest:

• Tegavivint (BC2059): A small molecule that disrupts the interaction between beta-catenin and TBL1, promoting beta-catenin degradation. This would be the most direct therapeutic approach against the fundamental driver of desmoid tumors. Early clinical data are being generated (NCT03459469).
• Other Wnt/beta-catenin pathway inhibitors: Several companies are developing drugs targeting various points in the Wnt pathway. While most are aimed at cancers, their relevance to desmoid tumors is clear given the shared biology.

Pazopanib was evaluated in the DESMOPAZ trial (NCT01876082) and showed activity. Other tyrosine kinase inhibitors that have been explored in case series or small studies include imatinib and sunitinib, though the evidence for these is limited. The success of sorafenib and pazopanib suggests this drug class has activity in desmoid tumors, and new-generation kinase inhibitors may offer improved efficacy or tolerability.

Cryoablation is increasingly being studied in controlled fashion (NCT02476305) rather than just case series. MRI-guided cryoablation and other percutaneous ablation techniques may become more standardized and widely available as data mature. The advantage of local ablation is that it can control a specific tumor without the systemic side effects of drug therapy, and without the high recurrence rates of surgery.

2000 Circle of Hope Drive, Salt Lake City, UT 84112
Main / new patients: 801-587-7000

NCI-designated Comprehensive Cancer Center for the Mountain West. Sarcoma and soft tissue tumor program, multidisciplinary tumor board, clinical trial access. The nearest major academic center for patients in Utah, Idaho, Montana, Wyoming, and Nevada.

New patients: 800-525-2225

One of the world’s leading desmoid tumor programs. Published extensively on desmoid tumor natural history, active surveillance, and systemic therapy. Runs a dedicated desmoid tumor clinic. Has treated among the largest cohorts of desmoid tumor patients globally. Also pioneered the active surveillance approach.

1515 Holcombe Boulevard, Houston, TX 77030
New patients: 877-632-6789

Extensive sarcoma and desmoid tumor program. Led or participated in major desmoid tumor clinical trials. One of the largest sarcoma programs in the world.

450 Brookline Avenue, Boston, MA 02215
New patients: 877-442-3324

Center for Sarcoma and Bone Oncology with desmoid tumor expertise. Active clinical trial program. Part of the Dana-Farber/Brigham and Women’s joint program with strong surgical and medical oncology teams.

Rochester: 507-538-3270  |  Phoenix/Scottsdale: 480-301-8000  |  Jacksonville: 904-953-0853

Multidisciplinary sarcoma programs at all three campuses. Experience with both sporadic and FAP-associated desmoid tumors. Established FAP/hereditary polyposis clinics that coordinate desmoid management with GI care.

• University of Michigan Rogel Cancer Center (Ann Arbor, MI) — 800-865-1125. Active sarcoma program with desmoid tumor expertise and trial access.
• Fred Hutchinson Cancer Center / University of Washington (Seattle, WA) — 206-606-7222. Sarcoma program with soft tissue expertise.
• Moffitt Cancer Center (Tampa, FL) — 888-663-3488. NCI-designated comprehensive cancer center with sarcoma services.
• Massachusetts General Hospital (Boston, MA) — 617-726-2000. Large sarcoma program with extensive soft tissue tumor experience.
• University of Colorado Cancer Center (Aurora, CO) — 720-848-0300. Nearest major academic center to Utah outside Huntsman. Sarcoma program.
• Cleveland Clinic (Cleveland, OH) — 866-223-8100. Musculoskeletal tumor center with soft tissue tumor expertise.

Memorial Sloan Kettering, MD Anderson, Mayo Clinic, and Dana-Farber also offer structured remote second-opinion programs that do not require travel.

Veterans diagnosed with desmoid tumors should contact the VA Oncology Service. The VA can facilitate referrals to NCI-designated cancer centers through community care agreements. Veterans Crisis Line: 988 (press 1). VA Health Benefits: 877-222-8387.

• Institut Bergonié (Bordeaux, France) — Part of the French Sarcoma Group. Led the DESMOPAZ trial and published extensively on desmoid tumor management. One of the most experienced desmoid tumor centers in Europe.
• Royal Marsden Hospital (London, UK) — 020 7352 8171. Major sarcoma center within the UK NHS. Part of the London Sarcoma Service.
• Istituto Ortopedico Rizzoli (Bologna, Italy) — Major European center for bone and soft tissue tumors.
• Leiden University Medical Centre (Leiden, Netherlands) — Active desmoid research program, particularly for FAP-associated disease.
• Princess Margaret Cancer Centre (Toronto, Canada) — 416-946-4501. Major Canadian sarcoma center with desmoid tumor expertise.
• Mount Sinai Hospital (Toronto, Canada) — Zane Cohen Centre for Digestive Diseases has a dedicated FAP and desmoid program.

Pain is the most common and often most debilitating symptom of desmoid tumors. It may result from the tumor pressing on nerves, infiltrating muscle or fascia, or causing inflammation. Pain management should be proactive and aggressive:

• First-line: NSAIDs and acetaminophen. For desmoid patients, NSAIDs may have the dual benefit of managing pain and potentially influencing tumor biology.
• Neuropathic pain: When the tumor involves nerves, neuropathic pain agents (gabapentin, pregabalin, duloxetine) may be more effective than traditional analgesics.
• Physical therapy: Critically important for maintaining function and managing pain, particularly for extremity desmoids. A physical therapist experienced with musculoskeletal oncology is ideal.
• Opioids: Used when other approaches are insufficient. Should be managed by a pain specialist when long-term use is anticipated.
• Interventional pain management: Nerve blocks, epidurals, and other interventional techniques may help selected patients.

Do not suffer in silence. Pain management can and should begin as soon as pain is present, regardless of whether the tumor itself is being treated. Many patients find that adequate pain control makes active surveillance much more tolerable.

Living with a chronic tumor — even one that is not cancer — takes a psychological toll. The uncertainty of active surveillance, the possibility of needing treatment, the chronicity of the condition, and the impact on daily life and plans can cause significant anxiety and depression. Resources include:

• Psycho-oncology services: Most sarcoma centers have psychologists or psychiatrists experienced with tumor patients.
• Peer support: Connecting with other desmoid tumor patients through the DTRF or online communities can reduce isolation.
• Mindfulness and stress reduction: Programs such as mindfulness-based stress reduction (MBSR) have shown benefit for patients with chronic medical conditions.

Exercise is generally safe and encouraged for patients with desmoid tumors, with appropriate modifications based on tumor location. For extremity desmoids, a physical therapist should guide the exercise program to avoid aggravating the tumor while maintaining strength and range of motion. For abdominal and trunk desmoids, general aerobic exercise is typically safe and beneficial for overall health and well-being. There is no strong evidence that exercise causes desmoid tumor growth.

Fertility is a significant concern for many desmoid tumor patients because the disease disproportionately affects young adults of reproductive age. Key considerations:

• Nirogacestat and ovarian function: Nirogacestat can cause ovarian dysfunction including premature ovarian failure. Premenopausal women should discuss fertility preservation (egg or embryo freezing) with a reproductive endocrinologist before starting treatment.
• Pregnancy and desmoid tumors: Pregnancy has been associated with desmoid tumor development and growth. Women with existing desmoid tumors who wish to become pregnant should discuss the risks with their sarcoma team. Some tumors grow during pregnancy; others remain stable.
• Methotrexate: This drug is teratogenic (causes birth defects) and must be discontinued well before conception in both men and women.
• Tamoxifen: Also teratogenic. Must be stopped before attempting pregnancy.

Supporting someone with a desmoid tumor has unique challenges. The condition is rare, which means few people understand it. It is not cancer, but it is not harmless either. Here are practical suggestions:

• Learn the basics. Understanding what a desmoid tumor is (and is not) helps you have informed conversations and reduces the fear of the unknown.
• Respect the uncertainty. Active surveillance can be particularly stressful for family members who want “something to be done.” Trust the medical team’s judgment that watching is often the best approach.
• Help with appointment logistics. Take notes at appointments, help track symptoms and imaging schedules, and ensure follow-up MRIs are not missed.
• Do not dismiss pain. Chronic pain from a desmoid tumor is real and debilitating, even though the tumor is not cancer. Validate the patient’s experience.
• Seek your own support. Caregiver burnout is real, even for a non-cancer condition. The DTRF and sarcoma organizations have resources for families.

• Can you confirm that this is a desmoid tumor (aggressive fibromatosis) and not a sarcoma? Has a soft tissue pathologist reviewed the biopsy?
• Where exactly is the tumor, and what is its current size?
• Has CTNNB1 mutation testing been done?
• Should I be tested for FAP (familial adenomatous polyposis)?
• Is active surveillance appropriate in my case? What would the monitoring schedule look like?
• How many desmoid tumor patients does this center treat per year?
• Should I get a second opinion at a sarcoma center?

• Why do you recommend treatment now rather than continued observation?
• Is nirogacestat (Ogsiveo) appropriate for my tumor? What response rate can I expect?
• If I am a premenopausal woman: what is the risk of ovarian toxicity with nirogacestat, and should I pursue fertility preservation first?
• What other systemic therapy options are there if nirogacestat is not appropriate?
• Are there clinical trials I should consider?
• What are the realistic goals of treatment — cure, shrinkage, stabilization, symptom improvement?
• How long will I need to be on treatment? What happens if I stop?

• Have we exhausted non-surgical options? What is the rationale for surgery now?
• What is the likelihood of achieving clear margins?
• What is the recurrence rate after surgery for a tumor in my location?
• What are the functional consequences of the operation?
• How many desmoid tumor surgeries have you performed?
• If margins are positive, would you recommend re-excision, observation, or medical therapy?

• What can I do to manage my pain more effectively?
• Are there activity restrictions I need to follow?
• How will this affect my ability to work, exercise, or travel?
• If I want to become pregnant, how does that interact with my desmoid tumor and any treatments?
• What support resources do you recommend?
• Honestly, what should I expect over the next few years?

• The treating center’s financial counseling office. At Huntsman, a patient financial advocate is assigned to new patients (801-587-7000). They help with insurance navigation, copay assistance, and payment plans.
• SpringWorks Therapeutics patient assistance: The manufacturer of nirogacestat (Ogsiveo) offers SpringWorksAssist, a patient access program for uninsured or underinsured patients. Contact via the prescribing center or springworkstx.com.

• Patient Advocate Foundation — case management and copay relief. 800-532-5274. patientadvocate.org
• CancerCare — financial-assistance grants, counseling, education. 800-813-4673. cancercare.org (serves sarcoma/rare tumor patients)
• HealthWell Foundation — copay assistance for specific drugs. 800-675-8416. healthwellfoundation.org
• PAN Foundation — copay assistance. 866-316-7263. panfoundation.org
• NeedyMeds — database of prescription-assistance programs. 800-503-6897. needymeds.org

• Desmoid Tumor Research Foundation (DTRF) — the primary patient organization. Education, support, research funding, clinical trial navigation, annual patient summit. dtrf.org
• Sarcoma Foundation of America — research funding, patient resources, support groups. curesarcoma.org
• Sarcoma Alliance — guidance, education, and support for sarcoma patients. sarcomaalliance.org
• SARC (Sarcoma Alliance for Research through Collaboration) — clinical trial consortium. sarctrials.org
• National Organization for Rare Disorders (NORD) — patient assistance programs, disease information, research grants. rarediseases.org. 203-744-0100.

• Social Security Disability Insurance (SSDI) — 800-772-1213. ssa.gov
• Medicare — 800-633-4227. medicare.gov
• Medicaid (Utah) — medicaid.utah.gov; 1-866-435-7414
• FMLA — job-protected leave for patient and family caregivers; apply through employer.
• American Cancer Society — lodging (Hope Lodge), 24/7 help line. 800-227-2345. cancer.org
• Mercy Medical Angels — ground and air transportation. mercymedical.org
• Joe’s House — lodging assistance for treatment travel. joeshouse.org

The FDA approved nirogacestat (Ogsiveo) in November 2023 for adult patients with progressing desmoid tumors who require systemic treatment. This made the US the first country to have a specifically approved therapy for desmoid tumors. Other systemic agents (sorafenib, methotrexate, vinorelbine, tamoxifen, celecoxib) are used off-label. NCCN Soft Tissue Sarcoma Guidelines include a dedicated desmoid tumor section.

The European Commission approved nirogacestat (Ogsiveo) on August 18, 2025 (following a positive CHMP opinion in June 2025) for adults with progressing desmoid tumors who require systemic therapy. Access and reimbursement timelines vary by individual EU member state. The ESMO-EURACAN guidelines (updated 2024) provide the primary European clinical reference and strongly emphasize active surveillance as the initial approach. In the UK, NICE appraisals determine NHS funding access. Patients should ask about the Cancer Drugs Fund or Individual Funding Requests as potential access pathways.

Nirogacestat approval status in Japan should be verified with current PMDA resources. The Japanese Orthopaedic Association guidelines address desmoid tumor management. Off-label agents (sulindac, tamoxifen, methotrexate-based regimens) are used. Japanese centers with sarcoma expertise include the National Cancer Center Hospital (Tokyo) and Osaka International Cancer Institute.

Nirogacestat’s Health Canada approval status is not confirmed — check the Health Canada Drug Product Database for the current status. Provincial formulary coverage may vary, and the pan-Canadian Oncology Drug Review (pCODR) issues funding recommendations. Patients facing access barriers should ask about special access programs. Princess Margaret Cancer Centre (Toronto) and Mount Sinai Hospital (Toronto, for FAP-associated desmoids) are the main Canadian referral centers.

TGA status for nirogacestat should be verified with current regulatory resources. Off-label agents are available through the PBS for some indications. Peter MacCallum Cancer Centre (Melbourne) and Royal Prince Alfred Hospital (Sydney) have sarcoma programs.

• Routine first-line surgery for all desmoid tumors DE-ADOPTED
  For decades, surgery was the default first treatment. Recurrence rates of 25–70% and the recognition that many tumors stabilize or regress spontaneously led both NCCN and ESMO-EURACAN to move away from surgery as the initial approach. Active surveillance is now preferred for most patients, with surgery reserved for selected situations.
• Routine adjuvant radiation after surgery DE-ADOPTED
  Post-operative radiation was once commonly recommended to reduce recurrence after desmoid surgery. Evidence that it reduces recurrence is inconsistent, and the long-term risks (fibrosis, secondary malignancy in a young patient population) have led to its de-emphasis. It is no longer routinely recommended after surgery.
• Imatinib (Gleevec) as a primary treatment LIMITED ACTIVITY
  Imatinib was tried based on its success in gastrointestinal stromal tumors (GIST). Studies showed only modest activity in desmoid tumors, with low response rates. It is no longer considered a recommended option given the availability of more effective agents (nirogacestat, sorafenib).
• Interferon-alpha LIMITED ACTIVITY
  Interferon-alpha was reported to have some activity in case reports and small series, but responses were modest and the side-effect burden (flu-like symptoms, fatigue, depression) was significant. It is no longer commonly used.
• High-dose aggressive chemotherapy DE-ADOPTED
  Aggressive sarcoma-type chemotherapy regimens (such as high-dose doxorubicin combinations) were sometimes used for rapidly progressive desmoid tumors. The toxicity of these regimens is disproportionate to the benefit for a non-malignant condition. Low-dose regimens and targeted therapies have replaced this approach.

• Active surveillance — a structured management approach involving regular monitoring with imaging and clinical assessment, without immediate treatment. Also called watchful waiting or observation.
• Aggressive fibromatosis — another name for desmoid tumor.
• APC gene — the gene mutated in familial adenomatous polyposis (FAP). APC mutations cause activation of the Wnt/beta-catenin pathway through a different mechanism than CTNNB1 mutations.
• Beta-catenin — a protein that, when it accumulates abnormally in the cell nucleus, drives the growth of desmoid tumors. Encoded by the CTNNB1 gene.
• Biopsy — removal of a small tissue sample for examination under a microscope. Core needle biopsy is preferred for desmoid tumor diagnosis.
• CTNNB1 — the gene encoding beta-catenin. Mutations in this gene (T41A, S45F, S45P) are found in the majority of sporadic desmoid tumors and drive their growth.
• Cryoablation — a minimally invasive technique that destroys tumor tissue by freezing it through a needle placed under imaging guidance.
• Desmoid-type fibromatosis — the WHO-preferred term for desmoid tumor. Classified as intermediate (locally aggressive), not malignant.

• FAP (familial adenomatous polyposis) — an inherited condition caused by APC gene mutations, leading to hundreds of colon polyps and increased risk of desmoid tumors (10–30% of FAP patients).
• Fibroblast — the cell type that makes connective tissue (collagen, tendons, ligaments). Desmoid tumors arise from fibroblasts.
• Gamma-secretase — an enzyme complex targeted by nirogacestat. It is involved in the Notch signaling pathway, which cross-talks with the Wnt pathway driving desmoid tumors.
• Gardner syndrome — a variant of FAP characterized by colonic polyposis plus desmoid tumors, osteomas, and epidermoid cysts.
• Mesentery — the fan-shaped tissue that suspends the intestines within the abdominal cavity and carries blood vessels to them. A common site for FAP-associated desmoid tumors.
• Methotrexate — a low-dose chemotherapy agent used in combination with vinblastine or vinorelbine for desmoid tumors. Very different from the high doses used in cancer treatment.
• MRI (magnetic resonance imaging) — the preferred imaging modality for monitoring most desmoid tumors. Provides excellent soft tissue detail without radiation exposure.
• Multikinase inhibitor — a drug that blocks multiple signaling pathways simultaneously. Sorafenib is a multikinase inhibitor used for desmoid tumors.
• Nirogacestat (Ogsiveo) — the first FDA-approved drug specifically for desmoid tumors. A gamma-secretase inhibitor. Approved November 2023 based on the DeFi trial.
• Notch pathway — a cell signaling pathway involved in desmoid tumor biology. Targeted by gamma-secretase inhibitors like nirogacestat.

• R0 resection — surgical removal of a tumor with microscopically clear margins (no tumor cells at the edge of the removed tissue).
• Recurrence — regrowth of a desmoid tumor after treatment, particularly after surgery. Desmoid tumors have high recurrence rates (25–70% after surgery).
• Sorafenib — an oral multikinase inhibitor with demonstrated activity in desmoid tumors (Alliance A091105 trial). Used off-label.
• Spontaneous regression — shrinkage or disappearance of a desmoid tumor without any treatment. Occurs in roughly 10–28% of cases.
• Sulindac — an NSAID used for desmoid tumors, particularly in FAP patients where it also helps control polyp burden.
• T2 signal — a characteristic on MRI. In desmoid tumors, high T2 signal may indicate active/cellular tumor, while low T2 signal may suggest mature, fibrous (less active) tissue.
• Tamoxifen — an anti-estrogen drug used for desmoid tumors based on case series data. Modest activity.
• Tyrosine kinase inhibitor (TKI) — a class of drugs that blocks signaling through tyrosine kinase enzymes. Sorafenib and pazopanib are TKIs used in desmoid tumors.
• Wnt/beta-catenin pathway — the central signaling pathway driving desmoid tumor growth. Activated by CTNNB1 mutations (sporadic tumors) or APC loss (FAP-associated tumors).

Guidelines:

• NCCN Clinical Practice Guidelines — Soft Tissue Sarcoma (current version, includes Desmoid Tumors section)
• Desmoid Tumor Working Group — global consensus on the management of desmoid tumours (Eur J Cancer 2020; updated JAMA Oncology 2024)
• WHO Classification of Tumours: Soft Tissue and Bone Tumours, 5th Edition (2020)

Landmark trials referenced in this guide:

• Desmoid Tumor Research Foundation (DTRF) (dtrf.org) — The primary patient organization for desmoid tumors. Education, support, research, clinical trial navigation.
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials. Search “desmoid” or “aggressive fibromatosis.”
• NCCN Guidelines for Patients (nccn.org/patientresources) — Free patient-friendly soft tissue sarcoma guidelines (includes desmoid tumors).
• National Cancer Institute (cancer.gov) — Desmoid tumor information and trial search (1-800-4-CANCER).
• Sarcoma Foundation of America (curesarcoma.org) — Research and patient support.
• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research.
• National Organization for Rare Disorders (NORD) (rarediseases.org) — Rare disease information and patient assistance. 203-744-0100.